United States, Good Manufacturing Practice regulations

Process validation is a requirement of the FDA Current Good Manufacturing Practices Regulations for Finished Pharmaceuticals, 21 CFR Parts 210 and 211, and of the Good Manufacturing Practice Regulations for Medical Devices, 21 CFR Part 820, and therefore, is applicable to the manufacture of pharmaceuticals and medical devices intended for the United States. 

Food and pharmaceutical grades of calcium carbonate are covered by the Food Chemicals Codex (7) and the United States Pharmacopeia (8) and subject to U.S. Food and Dmg Administration Good Manufacturing Practices (9). Both purity requirements and test methods are available (7,8). Calcium carbonate is listed in the U.S. Code of Federal Regulation as a food additive, and is authorized for use in both paper and plastic food contact appHcations. 

Decaffeination Regulations. Eor decaffeinated roasted coffee, EEC standards indicate the maximum content of caffeine as 0.1% db for decaffeinated instant coffee it is 0.3% db. In the United States, decaffeination usually signifies that 97% of the caffeine has been removed. Permissible solvents for decaffeination processes are defined by national legislation, eg, EDA or EEC directive. The maximum residual solvent content after decaffeination, roasting, or instant coffee processing is to be kept within good manufacturing practice, ie, very low ppm levels or below at point of sale (46). 

Production Facilities. The manufacture of acceptable cosmetic products requires not only safe ingredients but also faciUties that maintain high standards of quaUty and cleanliness. Most countries have estabUshed regulations intended to assure that no substandard product or batch is distributed to consumers. Good Manufacturing Practices (GMP) represent workable standards that cover every aspect of dmg manufacture, from building constmction to distribution of finished products. GMPs in the United States that have been estabUshed for dmg manufacture are commonly used in cosmetic production (6,25). 

Parts 210 and 211 of CFR Title 21 are the laws defining good manufacturing practices for finished pharmaceutical products. All manufacturers must follow these regulations in order to market their products in the United States. When a firm files an application to market a product in the United States through a New Drug Application (NDA), abbreviated NDA, (ANDA), Biological License Application (BLA),... 

Important protocols for method validation in the literature have been derived, amongst others, from the Current Good Manufacturing Practice, Code of Federal Regulations, Food and Drug Administration, National Drug Administration, the United States Pharmacopoeia Convention, the American Public Health Association and the International Conference on Harmonization. 

---